MB4090 / Mustbio - LARVOL DELTA

Isolation of high yield polyhydroxyalkanoate producing bacteria from contaminated soils and biopolymer characterization. (PubMed, Sci Rep) - "Five strains Paenibacillus lautus (MA2), Alcaligenes pakistanensis (MA3), Acinetobacter baumannii (MB1), Bacillus cereus (MB4), and Bacillus tropicus (MC3) were identified via 16 S rRNA sequencing against the NCBI BLAST database...Proton nuclear magnetic resonance (¹H NMR) confirmed copolymer composition, with 3-hydroxybutyrate signals at δ 1.28 ppm (CH₃), δ 2.56 ppm (CH₂-CO-), and δ 5.25 ppm (-CH-O-); 3-hydroxyvalerate peaks appeared at δ 0.9 ppm (terminal CH₃), δ 1.6-1.8 ppm (CH₂-), and δ 2.4-2.6 ppm (CH₂-CO-). These findings affirm the biopolymers' authenticity and versatility, supporting applications in biomedicine, biotechnology, and sustainable manufacturing."

Journal

A highly TME-selective αPD-1/αVEGF/IL-2v tri-specific fusion protein demonstrates potent anti-tumor activity beyond αPD-1/αVEGF therapy (SITC 2025) - "Consistent with the in vitro results, αPD-1/αVEGF/IL-2v demonstrated superior anti-tumor efficacy without body weight loss in TKI-resistant lung cancer bearing humanized mice, compared to αPD-1 or αPD-1/αVEGF bsAbs.Conclusions αPD-1/αVEGF/IL-2v is a highly TME-selective tri-specific fusion protein designed to enhance anti-tumor efficacy with favorable tolerability. These preclinical findings suggest that αPD-1/αVEGF/IL-2v holds therapeutic potential as a next-generation immunotherapy capable of overcoming the limitations of current αPD-1 or αPD-1/αVEGF-based therapies."

Trispecific • Lung Cancer • Oncology • Solid Tumor • CD8 • IL2